Los Angeles Biotech Trending News

AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE

EMERYVILLE, Calif. and CULVER CITY, Calif.: EMERYVILLE, Calif. and CULVER CITY, Calif., Jan. 3, 2022 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market […]

No Picture
News

Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

NEW YORK: NEW YORK, Jan. 3, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential […]

No Picture
Los Angeles Biotech Trending News

Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva […]

No Picture
Los Angeles Biotech Trending News

Opinion: Will the Biden administration use ‘march-in’ to protect prostate cancer patients from excessive drug prices?

Failing to grant a hearing on the Xtandi march-in petitions would signal that the federal government will continue to be a paper tiger when it comes to demonstrably unreasonable drug… Click to view original post